- Home
- PLL vs CDXS Comparison
PLL vs CDXS Comparison
Compare PLL & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- CDXS
- Stock Information
- Founded
- PLL 2016
- CDXS 2002
- Country
- PLL United States
- CDXS United States
- Employees
- PLL N/A
- CDXS N/A
- Industry
- PLL Other Metals and Minerals
- CDXS Major Chemicals
- Sector
- PLL Basic Materials
- CDXS Industrials
- Exchange
- PLL Nasdaq
- CDXS Nasdaq
- Market Cap
- PLL 217.1M
- CDXS 204.6M
- IPO Year
- PLL 2017
- CDXS 2010
- Fundamental
- Price
- PLL $6.68
- CDXS $2.74
- Analyst Decision
- PLL Buy
- CDXS Buy
- Analyst Count
- PLL 8
- CDXS 3
- Target Price
- PLL $25.47
- CDXS $10.50
- AVG Volume (30 Days)
- PLL 528.8K
- CDXS 317.5K
- Earning Date
- PLL 11-04-2024
- CDXS 10-31-2024
- Dividend Yield
- PLL N/A
- CDXS N/A
- EPS Growth
- PLL N/A
- CDXS N/A
- EPS
- PLL N/A
- CDXS N/A
- Revenue
- PLL $66,444,999.00
- CDXS $60,890,000.00
- Revenue This Year
- PLL $191.01
- CDXS N/A
- Revenue Next Year
- PLL $4.80
- CDXS $1.68
- P/E Ratio
- PLL N/A
- CDXS N/A
- Revenue Growth
- PLL N/A
- CDXS N/A
- 52 Week Low
- PLL $6.58
- CDXS $1.45
- 52 Week High
- PLL $46.33
- CDXS $4.91
- Technical
- Relative Strength Index (RSI)
- PLL 35.29
- CDXS 37.29
- Support Level
- PLL $7.40
- CDXS $2.72
- Resistance Level
- PLL $8.11
- CDXS $3.17
- Average True Range (ATR)
- PLL 0.68
- CDXS 0.16
- MACD
- PLL -0.06
- CDXS -0.01
- Stochastic Oscillator
- PLL 3.59
- CDXS 12.24
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.